Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2013Current Vascular Pharmacology

Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target

View Full Paper
Ask AI
Bookmark
Share

Key result

This review summarizes current knowledge on von Willebrand factor as a risk factor, mediator, and pharmacological target in the pathogenesis and treatment of thrombosis.

Design

Review

Authors

PLPeter J. LentingCDCécile V. DenisNWNikolett Wohner

Discussion

Loading...

Member takes

Overview

von Willebrand factor targeting warrants further study; leaves open its role in routine thrombosis management.

PICO

P
Population
Thrombosis
E
Exposure / Comparator
Von Willebrand Factor (VWF)

This review summarizes the current knowledge on von Willebrand factor as a risk factor, mediator, and pharmacological target in thrombosis.

Cite This Study

Lenting et al. (2013) conducted a review in Thrombosis. Von Willebrand Factor (VWF) was evaluated. This review summarizes current knowledge on von Willebrand factor as a risk factor, mediator, and pharmacological target in the pathogenesis and treatment of thrombosis.

synapsesocial.com/papers/6a9e8a57a96c65a64bd6ee87https://doi.org/10.2174/1570161111311040008
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders.2025
  2. 2Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target2017 · 57 citations
  3. 3Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence2018 · 46 citations
  4. 4The role of von Willebrand factor in hemostasis pathology2023 · 4 citations
  5. 5Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease2013 · 25 citations